Traws Pharma, Inc.

NasdaqCM:TRAW Stock Report

Market Cap: US$10.3m

Traws Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TRAW?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders319,7804%
Hedge Funds591,0007.4%
Private Companies605,5317.58%
VC/PE Firms605,5317.58%
Institutions699,0648.75%
General Public5,169,96164.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 119.9%.

Top Shareholders

Top 25 shareholders own 35.3% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.58%
OrbiMed Advisors LLC
605,531US$781.1k0%0.01%
7.58%
Viriom Inc.
605,531US$781.1k820%no data
7.4%
Squadron Capital Management Llc
591,000US$762.4k0%no data
4.13%
Adage Capital Management, L.P.
330,000US$425.7k0%no data
1.88%
Vestal Point Capital, LP
150,000US$193.5k0.13%0.01%
1.23%
Werner Cautreels
98,348US$126.9k2.08%no data
1.09%
The Vanguard Group, Inc.
87,259US$112.6k562%no data
1.05%
Nikolay Savchuk
83,562US$107.8k-66.7%no data
1.05%
Iain Dukes
83,562US$107.8k468%no data
0.54%
Geode Capital Management, LLC
43,440US$56.0k21.6%no data
0.36%
Ikarian Capital, LLC
28,493US$36.8k0%0.01%
0.31%
Robert Redfield
24,375US$31.4k0%no data
0.31%
Charles Pauza
24,375US$31.4k0%no data
0.28%
Two Sigma Investments, LP
22,018US$28.4k37.1%no data
0.16%
Hudson River Trading LLC
12,573US$16.2k0%no data
0.13%
XTX Markets Limited
10,708US$13.8k0%no data
0.12%
BlackRock, Inc.
9,956US$12.8k0%no data
0.044%
Citigroup Inc.
3,528US$4.6k5,780%no data
0.037%
Steven Fruchtman
2,992US$3.9k0%no data
0.02%
Mark Guerin
1,570US$2.0k313%no data
0.011%
James Marino
853US$1.1k0%no data
0.009%
Morgan Stanley
719US$927.70%no data
0.002%
SBI Holdings, Inc.
162US$209.30%no data
0.0017%
Mary Shoemaker
135US$174.20%no data
0.0012%
Vermillion & White Wealth Management Group LLC
96US$123.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 19:48
End of Day Share Price 2026/01/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Traws Pharma, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael Thomas CooperEdison Investment Research
Etzer DaroutGuggenheim Securities, LLC
Michael SchmidtGuggenheim Securities, LLC